PubMed: Exploring potential anti-inflammatory effects of medicinal cannabis

PubMed: Exploring potential anti-inflammatory effects of medicinal cannabis

Support Care Cancer. 2023 Oct 14;31(12):629. doi: 10.1007/s00520-023-08069-8.

ABSTRACT

PURPOSE: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.

METHOD: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.

RESULTS: There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.

CONCLUSION: We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.

TRIAL REGISTRATION: ANZCTR 26180001220257, registered 20/07/2018.

PMID:37837446 | DOI:10.1007/s00520-023-08069-8

https://pubmed.ncbi.nlm.nih.gov/37837446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1NqsX9BbHlDygQ8TcgAlJilHgPpiuKQtyIr–a3-xbLzPoB9xM&fc=20220928170152&ff=20231015190548&v=2.17.9.post6+86293ac October 14, 2023 10:00 am